Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 109
Trials in obesity and other serious chronic disease areas
building on the semaglutide molecule
Planned or ongoing trials with semaglutide
addressing other serious chronic diseases
Ongoing phase 2 trial with daily semaglutide vs
placebo in patients with NASH
semaglutide
Obesity
NASH
CVD
CKD
CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease
changing
diabetes®
semaglutide 0.4 mg sc QD
372
patients¹
semaglutide 0.2 mg sc QD
semaglutide 0.1 mg sc QD
Placebo 0.1, 0.2 or 0.4 mg
Liver biopsy
(recent or new)
72 weeks
Liver biopsy
Next steps:
Phase 2 trial expected to complete 2020
1 Inclusion criteria: Histological confirmation of NASH, BMI 25-45 kg/m², NASH fibrosis
stage 2 or 3, Histological NAFLD Activity Score ≥ 4
mg: Milligram; sc: Subcutaneous; QD: Once-daily; MR: Magnetic resonance;
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis
novo nordiskView entire presentation